CERE
Cerevel Therapeutics Holdings Inc (CERE)
$28.965.31%▲
Market is closedMarket is closed – opens on 8 PM, 01 Dec 2022
– opens on 8 PM, 01 Dec 2022
Key Stats
$27.39
Day's Range
$29.01
$19.86
52-Week Range
$41.46
| Returns | |
| 1 month return | 1.23% |
| 3 month return | 2.82% |
| 1 year return | 3.98% |
| 5 year return | 193.12% |
Company Information
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson's, epilepsy, schizophrenia and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
| Organization | Cerevel Therapeutics Holdings Inc |
| Employees | 285 |
| CEO | Dr. N. Anthony Coles Jr., M.P.H. |
| Industry | Finance |
Analyst Recommendation
based on 16 analysts ratings
Buy
81%
Buy
18%
Hold
0%
Sell
Based on 16 Wall street analysts offering stock ratings for Cerevel Therapeutics Holdings Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 39.5%Current
$28.96
Target
$40.4
Recommendation Trend
Based on 16 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 13 | 10 | 10 |
| Hold | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Highlights
| Market Capitalization | 4.5B |
| Book Value | $3.86 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.71 |
| Wall Street Target Price | 40.4 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 7.12 |
| Enterprise Value | 3.7B |
| Enterprise Value/Revenue | 0.0 |
| Enterprise Value/Ebitda | -12.0 |
Technicals
| Beta | 1.64 |
| 50 Day MA | 27.78 |
| 200 Day MA | 29.05 |
Institutional Holdings
Bain Capital Investors LLC
38.79%
FMR Inc
14.23%
T. Rowe Price Associates, Inc.
4.03%
Vanguard Group Inc
3.76%
Perceptive Advisors LLC
3.25%
Federated Hermes Inc
1.99%
Discover more
Frequently Asked Questions
What is Cerevel Therapeutics Holdings Inc share price today?
Can Indians buy Cerevel Therapeutics Holdings Inc shares?
How can I buy Cerevel Therapeutics Holdings Inc shares from India?
Can Fractional shares of Cerevel Therapeutics Holdings Inc be purchased?
What are the documents required to start investing in Cerevel Therapeutics Holdings Inc stocks?
What are today’s High and Low prices of Cerevel Therapeutics Holdings Inc?
What are today’s traded volumes of Cerevel Therapeutics Holdings Inc?
What is today’s market capitalisation of Cerevel Therapeutics Holdings Inc?
What is the 52 Week High and Low Range of Cerevel Therapeutics Holdings Inc?
How much percentage Cerevel Therapeutics Holdings Inc is down from its 52 Week High?
How much percentage Cerevel Therapeutics Holdings Inc is up from its 52 Week low?
What are the historical returns of Cerevel Therapeutics Holdings Inc?
Who is the Chief Executive Officer (CEO) of Cerevel Therapeutics Holdings Inc?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*